Special Issue "Marine Lipopolysaccharides"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: 30 April 2015
Prof. Dr. Antonio Molinaro
Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Complesso Universitario Monte Santangelo, Via Cintia 4, I-80126 Napoli, Italy
Phone: +39 081 674 123
Fax: +39 081 674 393
Interests: carbohydrates; lipopolysaccharides; polysaccharides; innate immunity; glycoconjugates; NMR
Marine bacteria are microorganisms that have adapted, through millions of years, to the survival in environments often characterized by one or more physico-chemical extreme parameters, such as pressure, temperature and salinity. The main interest in the research about marine bacteria is due to their ability to produce several biologically active molecules, such as antibiotics, toxins and antitoxins, antitumor and antimicrobial agents.
Lipopolysaccharides, LPSs, composing about 75% of the outer membrane of Gram negative bacteria and exposed toward the external environment, play an essential role in the adaptation of the organisms to the peculiar external surroundings. The study of LPS primary structure and the (supra)molecular architecture of such molecules is related to the possibility of thriving in marine habitats, shielding the cell from the disrupting action of natural stress factors.
LPSs are build up according to a common structural architecture and are composed of a hydrophilic hetero-polysaccharide (formed by core oligosaccharide and O-specific polysaccharide or O-chain) covalently linked to a lipophilic moiety termed lipid A, which is embedded in the outer leaflet and anchors these macromolecules to the membrane through electrostatic and hydrophobic interactions. LPSs not containing O-chain are termed Rough (R-) LPSs or lipooligosaccharides (LOSs). LOSs may occur in both wild and laboratory strains possessing mutations in the genes encoding the O-specific polysaccharide biosynthesis or transfer. Lipid A possesses a rather conservative structure consisting of α-(1→6)-glucosamine disaccharide backbone phosphorylated at positions 1 and 4’ and acylated with primary 3-hydroxy fatty acids at positions 2 and 3 of both GlcN residues; the hydroxyl groups of the primary fatty acids can be further acylated by secondary acyl moieties. In the core oligosaccharide an inner and outer region are usually distinguished: the inner core, proximal to the lipid A, consists of typical monose residues as Kdo (3-deoxy-D-manno-ocutolonic acid) and heptoses, often carrying negatively charged groups. Kdo is attached to the GlcN II of lipid A backbone and is the first sugar of the core oligosaccharide. The outer core region is more variable and is usually composed by hexoses. The LPS adaptive and dynamic changes managed by Gram-negative bacteria act on the carbohydrate backbone, on the polar heads and the acyl chain composition, and show the primary protective role that the LPSs operate in bacteria.
Another main reason to study LPS structure from marine bacteria is that the LPS lipid A is the primary immuno-stimulator centre of Gram negative bacteria, it triggers the activation of the innate immune system of eukaryotics (both animals and plants) through the interaction with particular proteins called pathogen related receptors, such as the toll like receptors in mammals. The toxicity of the lipid A is depending on its primary structure. The study of lipid A structures from non-toxic Gram-negative bacteria is extremely important in order to identify lipid A analogues which can antagonise the biological activation of competent mammalian host-cells by lipid A. Within this frame, lipopolysaccharides (LPSs), or their portions, from marine bacteria, have often shown low virulence, and represent potential candidates in the development of drugs to prevent septic shock.
The primary and secondary structure of a lipopolysaccharide is attained by a combinatiuon of chemical and biochemical techniques and state-of-art MS spectrometry and NMR spectroscopy.
Prof. Dr. Antonio Molinaro
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed Open Access monthly journal published by MDPI.
- lipid A
- marine bacteria
- NMR spectroscopy
- mass spectrometry
Mar. Drugs 2014, 12(7), 4260-4273; doi:10.3390/md12074260
Received: 8 April 2014; in revised form: 10 June 2014 / Accepted: 4 July 2014 / Published: 23 July 2014| PDF Full-text (1001 KB) | HTML Full-text | XML Full-text
Review: Gram-Negative Marine Bacteria: Structural Features of Lipopolysaccharides and Their Relevance for Economically Important Diseases
Mar. Drugs 2014, 12(5), 2485-2514; doi:10.3390/md12052485
Received: 7 December 2013; in revised form: 3 March 2014 / Accepted: 8 April 2014 / Published: 30 April 2014| PDF Full-text (1065 KB) | HTML Full-text | XML Full-text
Article: Vibrio vulnificus MO6-24/O Lipopolysaccharide Stimulates Superoxide Anion, Thromboxane B2, Matrix Metalloproteinase-9, Cytokine and Chemokine Release by Rat Brain Microglia in Vitro
Mar. Drugs 2014, 12(4), 1732-1756; doi:10.3390/md12041732
Received: 28 December 2013; in revised form: 26 February 2014 / Accepted: 26 February 2014 / Published: 26 March 2014| PDF Full-text (785 KB) | HTML Full-text | XML Full-text
Review: The Role of Biophysical Parameters in the Antilipopolysaccharide Activities of Antimicrobial Peptides from Marine Fish
Mar. Drugs 2014, 12(3), 1471-1494; doi:10.3390/md12031471
Received: 10 February 2014; in revised form: 3 March 2014 / Accepted: 3 March 2014 / Published: 13 March 2014| PDF Full-text (1254 KB) | HTML Full-text | XML Full-text
Mar. Drugs 2014, 12(3), 1495-1511; doi:10.3390/md12031495
Received: 8 December 2013; in revised form: 6 February 2014 / Accepted: 13 February 2014 / Published: 13 March 2014| PDF Full-text (1136 KB) | HTML Full-text | XML Full-text
Article: Structural Studies of the Lipopolysaccharide from the Fish Pathogen Aeromonas veronii Strain Bs19, Serotype O16
Mar. Drugs 2014, 12(3), 1298-1316; doi:10.3390/md12031298
Received: 24 December 2013; in revised form: 27 January 2014 / Accepted: 8 February 2014 / Published: 7 March 2014| PDF Full-text (1051 KB) | HTML Full-text | XML Full-text
Review: The Lipopolysaccharide Export Pathway in Escherichia coli: Structure, Organization and Regulated Assembly of the Lpt Machinery
Mar. Drugs 2014, 12(2), 1023-1042; doi:10.3390/md12021023
Received: 15 January 2014; in revised form: 22 January 2014 / Accepted: 28 January 2014 / Published: 17 February 2014| PDF Full-text (862 KB) | HTML Full-text | XML Full-text
Article: Influence of Lipid A Acylation Pattern on Membrane Permeability and Innate Immune Stimulation
Mar. Drugs 2013, 11(9), 3197-3208; doi:10.3390/md11093197
Received: 30 June 2013; in revised form: 29 July 2013 / Accepted: 9 August 2013 / Published: 26 August 2013| Cited by 1 | PDF Full-text (353 KB) | HTML Full-text | XML Full-text
Article: Structural and Immunochemical Studies of the Lipopolysaccharide from the Fish Pathogen, Aeromonas bestiarum Strain K296, Serotype O18
Mar. Drugs 2013, 11(4), 1235-1255; doi:10.3390/md11041235
Received: 25 February 2013; in revised form: 8 March 2013 / Accepted: 18 March 2013 / Published: 17 April 2013| Cited by 4 | PDF Full-text (922 KB) | HTML Full-text | XML Full-text | Supplementary Files
Mar. Drugs 2013, 11(1), 184-193; doi:10.3390/md11010184
Received: 11 December 2012; in revised form: 9 January 2013 / Accepted: 11 January 2013 / Published: 21 January 2013| PDF Full-text (605 KB) | HTML Full-text | XML Full-text | Supplementary Files
Last update: 7 May 2014